Kamen and Sequel Medtech CEO Alan Lotvin say they are offering greater precision in insulin delivery with new pump technology ...

Insulet saw strong insulin pump adoption among new users with Type 2 diabetes following its recent FDA clearance, while ...

PharmaSens announced today that it appointed Dr. Robert A. Gabbay and James L. Peterson to its board of directors.

Insulet raised its annual revenue growth forecast on Thursday, banking on strong demand for its wearable insulin pumps.

Thus, the pump may stop insulin delivery significantly sooner than ... life to determine whether replacement is necessary. The new alert updates a previous one issued in July.

Opens in a new tab or window A shorter-than-expected battery life prompted a voluntary recall of certain insulin pumps from Medtronic's MiniMed 600 and 700 series, the FDA detailed on Thursday.

Tandem Diabetes Care (TNDM) and Insulet (PODD) stocks draw outperform ratings at Bernstein as insulin pump makers prepare for ...

Analyst Jeff Johnson from Robert W. Baird maintained a Buy rating on Insulet (PODD – Research Report) and keeping the price target at ...

pump manufacturers, regulatory authorities, and policymakers can best ensure the safety of new and long-standing users of insulin pumps as the technology continues to develop. We gathered evidence ...

Insulet ( (PODD) ) has released its Q3 earnings. Here is a breakdown of the information Insulet presented to its investors. Insulet ...

The rising popularity of the continuous glucose monitor, which is not the same as an insulin pump, has been a huge advance in ...

PharmaSens, a developer of insulin patch pumps for people with diabetes, has appointed Robert A. Gabbay, MD, PhD, FACP and James L. Peterson to its board of directors.